ERBB2 and breast carcinoma: In March 2018, a Phase-I/II-trial treated patients with HR-positive, HER2-negative breast cancer, metastatic triple-negative breast cancer, or advanced cisplatin-resistant epithelial ovarian cancer/fallopian tube cancer [112].